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Abstract
Conversion of diploidy to haploidy is a method that allows the gener-
ation of stable murine/human hybrid cell lines carrying selected human
chromosomes in only a single copy. In this setting, it is possible to detect
genetic mutations with greater sensitivity and reliability than in diploid
cells. Using this method, we were able to identify mutations in the human
mismatch repair (MMR) gene hMSH2 in hereditary nonpolyposis colon
cancer families, which have escaped detection by the conventional meth-
ods. In this report, we show that such hybrid cell lines can also be a
valuable tool in the study of the mutated MMR proteins, in particular the
variants found in hereditary nonpolyposis colon cancer families that carry
missense mutations and where it is unclear whether they predispose to
colon cancer. This analysis is made possible by the fact that the human
hMSH2 protein is able to complement the MMR defect in the host murine
cell line.
Introduction
Germ-line mutations in hMSH2 or hMLH1 MMR3 genes are asso-
ciated with the predisposition to colorectal and endometrial cancers in
HNPCC families.4 A second somatic alteration in the wild-type allele
of these genes occurs early in colon carcinogenesis, thus inactivating
the MMR system. Because this system is devoted to the repair of
nucleotide misincorporations and misalignments occurring during
DNA replication, MMR-deficient tumors are characterized by a mu-
tator phenotype with a high frequency of microsatellite instability.
Conventional procedures identify germ-line mutations in 70% of
HNPCC kindred. In some cases, the failure to detect mutations has
been attributed to the interference of the wild-type sequence, which
masks the sequence of the mutated allele. To overcome this problem,
we have recently introduced conversion of diploidy to haploidy, a
procedure in which lymphocytes of HNPCC patients are fused with
mouse cells to obtain stable hybrid cell lines carrying the desired
maternal or paternal human chromosome (1). This highly sensitive
and reliable method enabled us to identify mutations in MMR genes
that had been undetectable using standard mutational analysis. We
were interested to find out whether these hybrid cell lines could also
be used to study the phenotypic changes associated with the germ-line
mutations. To this end, we analyzed the phenotypes of hybrids car-
rying a single copy of the human chromosome 2 mutated in hMSH2.
This was possible, because the human hMSH2 protein was able to
complement the MMR defect of the recipient murine cells, in which
both copies of the Msh2 gene had been inactivated.
Materials and Methods
Conversion of Diploidy to Haploidy. This procedure was performed as
described previously (1). Briefly, lymphocytes from HNPCC patients were
mixed with a hprt-deficient and geneticin-resistant clone of E2 cells, derived
from Msh2-deficient mouse embryonic fibroblasts. The cells were fused using
a BTX ElectroCell Manipulator, and hybrids resistant to both hypoxanthine-
aminopterin-thymidine and geneticin were selected and expanded for geno-
typing. Microsatellite markers linked to the hMSH2 locus were used to screen
for hybrids containing the maternal or the paternal hMSH2 allele (1). To test
hMSH2 mutations biochemically, several hybrids with either the wild-type or
the mutated allele from four HNPCC kindred were expanded in DMEM (Life
Technologies, Inc.) supplemented with 10% FCS, 2 mM L-glutamine, and
1  hypoxanthine-aminopterin-thymidine medium.
Western Blots. Cytoplasmic and nuclear extracts for Western blots and
MMR assays were prepared as described previously (2, 3). Fifty g of the
extracts were loaded on 7.5% SDS-polyacrylamide gels, and the separated
proteins were transferred onto membranes. These were first blocked with 50
mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.1% Tween 20, and 5% nonfat dry milk
for 1 h at 37°C and then incubated for 1 h with the following primary mAbs:
anti-hMSH2 mAb NA26 (Oncogene Research); anti-hMSH6 mAb 2D4 (4);
anti-hMLH1 mAb13271A (PharMingen); and anti--tubulin mAb N357 (Am-
ersham). The latter mAb was used as an internal standard for loading. Immu-
nodetection was carried out by using a horseradish peroxidase-linked anti-
mouse secondary antibody and ECL detection reagents (Amersham Pharmacia
Biotech).
MMR Repair Assay. The efficiency of the cell extracts in repairing DNA
mismatches was tested as described previously (5). Briefly, 5 ng of M13mp2
DNA heteroduplex containing a G/T mismatch in the coding sequence of the
lacZ  complementation gene were used in a repair reaction together with 50
g of cytoplasmic extract. The DNA heteroduplex was purified, introduced by
electroporation into Escherichia coli NR9162 (mutS strain), and plated on
minimal medium in a soft agar layer containing 0.5 ml of a log phase culture
of CSH50 (the -complementation strain), 0.5 mg of isopropyl--D-thiogalac-
topyranoside, and 2 mg of 5-bromo-4-chloro-3-indoyl--D-galactopyranoside.
After 20 h incubation at 37°C, plaques were assigned to one of the following
phenotypes: blue, colorless, or mixed. If no repair occurred, a high percentage
of mixed plaques containing both blue and colorless progeny was observed.
Reduction of mixed plaques and a concomitant increase in single-color plaques
were indicative of repair. Repair efficiency (%) was calculated as follows:
100  [1  (% mixed plaques in extract-treated sample)/ (% mixed plaques in
extract-untreated sample)]. The data obtained with this method were confirmed
by testing nuclear extracts with a different in vitro MMR assay (Ref. 3; data not
shown).
Temozolomide Sensitivity. The effect of temozolomide on the cell hybrids
was evaluated by the tetrazolium salt method (6). The cells were suspended (1
or 2  104 cells/ml, depending on the cell line) in DMEM supplemented with
10% FCS and 2 mM L-glutamine, dispensed in 50-l aliquots into 96-well
plates, and allowed to attach for 18 h at 37°C. Different amounts of temozo-
lomide (50–1400 M; Schering-Plough) were then added in 50 l of culture
medium, and plates were maintained at 37°C for 6 days. Four replicated wells
were used for controls and for each drug concentration. Sensitivity of hybrids
to temozolomide was also evaluated in the presence of O6-BG (Sigma), a
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specific inhibitor of MGMT. To this end, cells were plated as described above
and exposed to 20 M O6-BG for 2 h before temozolomide treatment. The
same inhibitor concentration was maintained in culture during the 6-day
treatment. Control groups were exposed to O6-BG alone. MGMT activity of
O6-BG-treated cells was evaluated according to the method described by
Morten and Margison (7). This activity was undetectable 2 h after the addition
of the inhibitor and remained abrogated up to the end of the assay (data not
shown). At the end of the incubation period, 20 l of a 5 mg/ml 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (Sigma) solution were
added, and the cells were incubated at 37°C for an additional 6 h. They were
then lysed with a buffer (0.1 ml/well) containing 20% SDS and 50% N,N-
dimethyl formamide (pH 4.7). After an overnight incubation, the absorbance
was read at 595 nm using a 3550-UV microplate reader (Bio-Rad). Cell
sensitivity to drug treatment was expressed in terms of IC50 (i.e., the drug
concentration capable of producing 50% inhibition of cell growth, calculated
on the regression line in which absorbance values at 595 nm were plotted
against the logarithm of drug concentration).
Results and Discussion
We studied proteins extracted from several hybrid cell lines carry-
ing hMSH2 alleles found in four HNPCC families (GJ, FM, W, and
SG kindred). Hybrids carrying normal hMSH2 alleles, as verified by
microsatellite analysis and sequencing (1), expressed full-length
hMSH2 (GJ8.2, GJ6.5, GJ8.1, FM10.5, W 12, W 26, and SG4 in Fig.
1). The hMSH2 and hMSH6 genes are closely linked on chromosome
2p, and it was expected that all hybrids carrying the former gene
would also carry the latter. In addition, hMSH6 is stabilized by
hMSH2 in the mismatch recognition complex hMutS (hMSH6/
hMSH2; Ref. 8). The presence of hMSH6 expression in each of these
hybrids was confirmed by Western blot analysis (Fig. 1). In contrast,
hMSH2 was absent in GJ 6, FM1.6, W 6, W 27, W 35, SG16, and
SG15 hybrids, which carry the mutated hMSH2 alleles (Fig. 1). This
was anticipated for three of these mutations, an out-of-frame deletion
of exon 12 (family GJ), an in-frame deletion of exon 5 (family FM),
and a 24-bp insertion between codons 215 and 216 (family W), which
bring about destabilization of hMSH2 mRNA or proteins (1, 9).
However, the A636P missense mutation in family SG also resulted in
destabilization of hMSH2 (SG16 and SG15 in Fig. 1, verified by a
lack of expression of the mutated protein in a baculovirus system),
whereas reverse transcription showed full-length mRNA expressed at
the same level as in the hybrid with the wild-type allele (data not
shown). This finding, which suggests that the A636P mutation also
predisposes to colon cancer, could be corroborated by the fact that it
was identified in three HNPCC kindred but not in 400 alleles from
normal individuals (10).5 The weak band visible at the level of
hMSH6 in extracts of hybrids carrying the mutated hMSH2 alleles
(Fig. 1) represents residual murine Msh6 protein in the msh2/
mouse recipient cells, which cross-reacts with the anti-hMSH6 anti-
body.
Two hybrids from each HNPCC family, one carrying the mutated
allele and the other the wild-type allele, were selected for further
analysis. Fig. 2a shows that extracts of all hybrid cell lines carrying
the wild-type hMSH2 alleles were proficient in in vitro MMR assays.
The recipient murine E2 cells do not express Msh2 and are thus MMR
deficient. The finding that extracts of hybrids expressing human
hMSH2 and hMSH6 are MMR proficient demonstrates that the hu-
man hMSH2/hMSH6 heterodimer can functionally interact with the
murine MMR factors that are downstream of mismatch recognition.
Our finding that the human hMSH2 can interact with its cognate
5 Internet address: http://www.nfdht.nl.
Fig. 1. Western blots showing the expression of hMSH2 and hMSH6 in hybrid cell
lines carrying hMSH2 alleles from families GJ, FM, W, and SG. LoVo, human colon
cancer line lacking hMSH2 and hMSH6; 413 MI and SG, human lymphoblastoid cell lines
immortalized from a normal subject and the index case of the SG family, respectively,
were used as a positive control; E2, Msh2-deficient murine recipient cell line. Hybrids
from families GJ, FM, and W were also tested for hMLH1 expression (arrow).
Fig. 2. In vitro MMR efficiency and temozolomide sensitivity of hybrids from the four
HNPCC families, carrying either the mutated () or the wild-type () alleles. Each value
represents the mean of two (MMR assay) or four (temozolomide sensitivity) independent
experiments; bars, SE. a, efficiency of repair of heteroduplex DNA containing a G/T
mismatch. b, temozolomide sensitivity of hybrid cell lines evaluated by the MTT assay,
either in the absence (plain columns) or in the presence (dashed columns) of 20 M
O6-BG, which inhibits the methylation-detoxifying enzyme MGMT and thus augments
the difference in sensitivity of each pair of hybrids attributable to the MMR function (see
text). Data from the recipient mouse cell line E2 are also shown.
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murine partners emphasizes the high degree of conservation of the
mammalian MMR system. It is further supported by the study of
Buermeyer et al. (11) who were able to complement Mlh1-deficient
mouse embryonic fibroblasts with hMLH1 cDNA. The variability in
the efficiency of the in vitro MMR reactions is also noteworthy. As
shown earlier (1), the electrofusion gives rise to hybrids that carry on
average 11  3 human chromosomes, and it is possible that some, but
not others, express other human proteins that participate in MMR.
Indeed, the data in Fig. 1 show that the MMR-proficient hybrids GJ
8.1 and W 26 also contain hMLH1, which is on chromosome 3.
MMR-deficient cells are generally more resistant to killing by
DNA-methylating agents than their MMR-proficient counterparts.
The primary reason underlying this phenomenon may be linked with
futile attempts of the MMR system in the latter cells to repair O6-
methyl-G/T mismatches, which may trigger apoptosis (12). We there-
fore wanted to test whether the hybrids carrying the mutated hMSH2
alleles were more resistant to killing by the methylating agent temo-
zolomide than those carrying the wild-type alleles. However, because
O6-methyl-G is efficiently processed by MGMT, which represents the
first line of defense against DNA damage caused by methylating
agents, the experiments were performed both in the presence and in
the absence of O6-BG, a specific inhibitor of MGMT (Fig. 2b). This
eliminated the possibility that the observed differences between hy-
brids were caused by different basal levels of MGMT. When MGMT
is inhibited by O6-BG, MMR-proficient cells become generally more
sensitive to killing by methylating agents, whereas MMR-deficient
cells tend to retain their basal level of tolerance (12, 13). Fig. 2b
shows that in the absence of O6-BG, the hybrid cell lines carrying the
mutated hMSH2 alleles () were more resistant (P  0.01, Student’s
t test) to temozolomide than hybrids with wild-type alleles (). As
expected, the tolerance of the MMR-deficient hybrids was not af-
fected by O6-BG treatment (Fig. 2b, 1), whereas the MMR-proficient
hybrids ( ) became more sensitive to temozolomide in the presence
of O6-BG (P  0.01, Student’s t test).
The functional characterization of inherited MMR gene alterations
is often required to distinguish pathogenic mutations from polymor-
phisms, especially in those HNPCC families where segregation stud-
ies are not possible. Such tests have been described (14, 15), but their
complexity precludes their use by most clinical laboratories. The fact
that human and mouse MMR proteins are complementary (Ref. 11
and this report) allowed us to analyze in vivo hybrid cells with a
simple laboratory test that reliably distinguishes cells with nonfunc-
tional hMSH2 proteins from cells with wild-type hMSH2. This was
possible because the tolerance to methylating agents represents a
characteristic phenotype of MMR-deficient cells. Similarly, it should
be possible to extend the functional approach proposed in this report
to the analysis of hMLH1 mutations by using recipient mouse
Mlh1/ cells and of other genes in genetic diseases where the
phenotype of the target protein can be assayed.
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